CN Patent

CN110494423B — 乐伐替尼甲磺酸盐的新晶型及其制备方法

Assigned to Crystal Pharmaceutical Suzhou Co Ltd · Expires 2022-04-26 · 4y expired

What this patent protects

本发明提供了乐伐替尼甲磺酸盐的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备酪氨酸酶抑制剂和治疗甲状腺癌药物制剂中的用途。本发明提供的甲磺酸盐新晶型制备成本优势明显，比现有技术具有一种或多种改进的特性，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明提供了乐伐替尼甲磺酸盐的新晶型及其制备方法，含有该晶型的药物组合物，以及该晶型在制备酪氨酸酶抑制剂和治疗甲状腺癌药物制剂中的用途。本发明提供的甲磺酸盐新晶型制备成本优势明显，比现有技术具有一种或多种改进的特性，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN110494423B
Jurisdiction: CN
Classification: —
Expires: 2022-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Crystal Pharmaceutical Suzhou Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.